Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.32 USD
Change Today -0.22 / -0.47%
Volume 15.4K
As of 9:47 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $58.73
52 Week Low
10/13/14 - $17.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase pathway and the tryptophan-(2.3)-dioxygenase pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy, is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for treating advanced non-small cell lung cancer; and HyperAcute Melanoma immunotherapy for treating advanced melanoma, as well as HyperAcute immunotherapies for renal, prostate, and breast cancers. In addition, the company is developing IDO pathway inhibitors comprising indoximod and NLG919 for metastatic breast cancer and metastatic prostate cancer; NLG2101 for patients with metastatic breast cancer; NLG2102 for treating refractory malignant brain tumors; NLG2103 for patients with advanced melanoma; and NLG2014 for patients with metastatic pancreatic cancer. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

130 Employees
Last Reported Date: 03/16/15
Founded in 1999

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $573.2K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $453.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $90.0K
Vice President of Business Development
Total Annual Compensation: $262.5K
Compensation as of Fiscal Year 2014.

newlink genetics corp (NLNK) Key Developments

Newlink Genetics Corporation Announces Vaccine Candidate Potentially Effective against Ebola in Large Trial in Guinea

NewLink Genetics Corporation announced that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate the development of this promising candidate. Merck is now responsible for research, development and manufacturing of the rVSV-ZEBOV vaccine. Because of the Ebola crisis, a large team was assembled which included scientists, physicians, epidemiologists and other experts from the World Health Organization (WHO), Norway, Canada, Guinea, Doctors without Borders, the Universities of Florida, Maryland and Bern, and the London School of Hygiene & Tropical Medicine. Funding for the trial came from the Wellcome Trust, Norway, Canada, WHO, and Doctors without Borders. NewLink Genetics and Merck (known as MSD outside the United States and Canada) provided the vaccine. Scientists from NewLink Genetics and Merck also gave detailed technical support on the vaccine and its administration to field trial staff.

NewLink Genetics Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

NewLink Genetics Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $7,445,000 compared with $212,000 a year ago. Net loss was $14,091,000 or $0.49 per basic and diluted share compared with $9,164,000 or $0.33 per basic and diluted share, a year ago. Loss from operations was $15,920,000 against $9,126,000 a year ago. For the six months, the company reported total revenue of $46,640,000 compared with $534,000 a year ago. Loss from operations was $3,094,000 against $18,431,000 a year ago. Net loss was $2,901,000 or $0.10 per basic and diluted share compared with $18,399,000 or $0.66 per basic and diluted share, a year ago.

NewLink Genetics Corporation to Report Q2, 2015 Results on Jul 31, 2015

NewLink Genetics Corporation announced that they will report Q2, 2015 results at 12:00 PM, GMT Standard Time on Jul 31, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $46.32 USD -0.22

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies

Industry Analysis


Industry Average

Valuation NLNK Industry Range
Price/Earnings 12.3x
Price/Sales 6.1x
Price/Book 5.9x
Price/Cash Flow 11.3x
TEV/Sales 5.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at